146 related articles for article (PubMed ID: 37067155)
1. Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species.
Zaki A; Gonzales-Luna AJ; Beyda ND; Lasco T; Garey KW
Pharmacotherapy; 2023 Jun; 43(6):466-472. PubMed ID: 37067155
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
5. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
6. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
7. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
[TBL] [Abstract][Full Text] [Related]
10. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
11. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
14. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
16. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
17. A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis.
Beredaki MI; Pournaras S; Meletiadis J
J Antimicrob Chemother; 2024 Jan; 79(1):157-165. PubMed ID: 38000088
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].
Thierry G; Morio F; Le Pape P; Gay-Andrieu F; Barre O; Miegeville M
Pathol Biol (Paris); 2011 Feb; 59(1):52-6. PubMed ID: 20832195
[TBL] [Abstract][Full Text] [Related]
19. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
